Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (75) 75
oncology (71) 71
life sciences & biomedicine (68) 68
breast cancer (64) 64
humans (63) 63
female (60) 60
breast neoplasms - drug therapy (41) 41
middle aged (38) 38
breast neoplasms - pathology (37) 37
adult (36) 36
chemotherapy (34) 34
tumors (34) 34
aged (29) 29
metastasis (27) 27
cancer therapies (24) 24
disease-free survival (22) 22
antineoplastic combined chemotherapy protocols - therapeutic use (21) 21
cancer (20) 20
patients (20) 20
treatment outcome (20) 20
erbb-2 protein (18) 18
trastuzumab (17) 17
metastases (16) 16
care and treatment (15) 15
antineoplastic combined chemotherapy protocols - adverse effects (13) 13
endocrine therapy (13) 13
prognosis (13) 13
research (13) 13
drug therapy (12) 12
studies (12) 12
survival (12) 12
biological and medical sciences (11) 11
clinical trials (11) 11
medical sciences (11) 11
medicine & public health (11) 11
aged, 80 and over (10) 10
analysis (10) 10
antineoplastic agents (10) 10
biomarkers (10) 10
breast neoplasms - genetics (10) 10
breast neoplasms - mortality (10) 10
drug administration schedule (10) 10
follow-up studies (10) 10
male (10) 10
receptor, erbb-2 - metabolism (10) 10
surgery (10) 10
antibodies, monoclonal, humanized - administration & dosage (9) 9
antineoplastic agents - therapeutic use (9) 9
chemotherapy, adjuvant (9) 9
gene expression (9) 9
gynecology. andrology. obstetrics (9) 9
kaplan-meier estimate (9) 9
mammary gland diseases (9) 9
mutation (9) 9
womens health (9) 9
breast neoplasms - metabolism (8) 8
dose-response relationship, drug (8) 8
hematology, oncology and palliative medicine (8) 8
medical prognosis (8) 8
metastatic breast cancer (8) 8
proportional hazards models (8) 8
time factors (8) 8
antibodies, monoclonal, humanized - adverse effects (7) 7
biomarkers, tumor - metabolism (7) 7
breast neoplasms - surgery (7) 7
general & internal medicine (7) 7
genes (7) 7
infusions, intravenous (7) 7
medicine, general & internal (7) 7
multidisciplinary sciences (7) 7
post-menopause (7) 7
receptors, estrogen - metabolism (7) 7
research article (7) 7
science & technology - other topics (7) 7
survival analysis (7) 7
tamoxifen (7) 7
abridged index medicus (6) 6
androstadienes - administration & dosage (6) 6
antineoplastic agents, hormonal - therapeutic use (6) 6
breast tumors (6) 6
epidermal growth factor (6) 6
estrogens (6) 6
everolimus (6) 6
fluorouracil - administration & dosage (6) 6
gene expression profiling (6) 6
genomics (6) 6
maximum tolerated dose (6) 6
medical research (6) 6
medicine (6) 6
paclitaxel (6) 6
paclitaxel - administration & dosage (6) 6
patient outcomes (6) 6
pharmacology. drug treatments (6) 6
quality of life (6) 6
safety (6) 6
science (6) 6
skin and connective tissue diseases (6) 6
toxicity (6) 6
1-phosphatidylinositol 3-kinase (5) 5
animals (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer
by Ciruelos Gil, Eva Maria
Cancer treatment reviews, ISSN 0305-7372, 2014, Volume 40, Issue 7, pp. 862 - 871
Hematology, Oncology and Palliative Medicine | Estrogen receptor | Endocrine resistance | PI3K | Mammalian target of rapamycin | mTOR | Endocrine therapy | Luminal type | Breast cancer | AKT | Phosphatidylinositol 3-kinase | MTOR | Life Sciences & Biomedicine | Oncology | Science & Technology | Gynecology. Andrology. Obstetrics | Mammary gland diseases | Pharmacology. Drug treatments | Biological and medical sciences | Multiple tumors. Solid tumors. Tumors in childhood (general aspects) | Medical sciences | Antineoplastic agents | Tumors | Receptors, Estrogen - metabolism | Signal Transduction - drug effects | TOR Serine-Threonine Kinases - metabolism | Humans | Female | Antineoplastic Agents - therapeutic use | Molecular Targeted Therapy | Proto-Oncogene Proteins c-akt - metabolism | Breast Neoplasms - drug therapy | Phosphatidylinositol 3-Kinase - metabolism | Breast Neoplasms - metabolism | Phenols | Development and progression | Chemotherapy | Estrogen | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
by Swain, Sandra M, Dr and Kim, Sung-Bae, MD and Cortés, Javier, MD and Ro, Jungsil, MD and Semiglazov, Vladimir, MD and Campone, Mario, MD and Ciruelos, Eva, MD and Ferrero, Jean-Marc, MD and Schneeweiss, Andreas, MD and Knott, Adam, PhD and Clark, Emma, MSc and Ross, Graham, FFPM and Benyunes, Mark C, MD and Baselga, José, MD
The lancet oncology, ISSN 1470-2045, 2013, Volume 14, Issue 6, pp. 461 - 471
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Double-Blind Method | Humans | Middle Aged | Kaplan-Meier Estimate | Proportional Hazards Models | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Treatment Outcome | Breast Neoplasms - drug therapy | Disease-Free Survival | Taxoids - administration & dosage | Breast Neoplasms - enzymology | Antibodies, Monoclonal, Humanized - administration & dosage | Time Factors | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Intention to Treat Analysis | Biomarkers, Tumor - metabolism | Breast Neoplasms - mortality | Female | Receptor, ErbB-2 - antagonists & inhibitors | Biomarkers, Tumor - antagonists & inhibitors | Molecular Targeted Therapy - methods | Trastuzumab | Patient outcomes | Analysis | Oncology, Experimental | Breast cancer | Metastasis | Research | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
by André, Fabrice and Ciruelos, Eva and Rubovszky, Gabor and Campone, Mario and Loibl, Sibylle and Rugo, Hope S and Iwata, Hiroji and Conte, Pierfranco and Mayer, Ingrid A and Kaufman, Bella and Yamashita, Toshinari and Lu, Yen-Shen and Inoue, Kenichi and Takahashi, Masato and Pápai, Zsuzsanna and Longin, Anne-Sophie and Mills, David and Wilke, Celine and Hirawat, Samit and Juric, Dejan and SOLAR-1 Study Grp and SOLAR-1 Study Group and the SOLAR-1 Study Group
The New England journal of medicine, ISSN 0028-4793, 05/2019, Volume 380, Issue 20, pp. 1929 - 1940
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Drug therapy | Development and progression | Breast cancer | Cyclin-dependent kinases | Diarrhea | Endocrine therapy | Metastasis | Kinases | Patients | Cancer therapies | Survival | ErbB-2 protein | Fulvestrant | Hyperglycemia | Chemotherapy | Epidermal growth factor | Antitumor activity | Diabetes | Mutation | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort
by Gianni, Luca, Dr and Eiermann, Wolfgang, MD and Semiglazov, Vladimir, MD and Lluch, Ana, PhD and Tjulandin, Sergei, MD and Zambetti, Milvia, MD and Moliterni, Angela, MD and Vazquez, Federico, MD and Byakhov, Mikhail J, PhD and Lichinitser, Mikhail, MD and Climent, Miguel Angel, MD and Ciruelos, Eva, MD and Ojeda, Belen, MD and Mansutti, Mauro, MD and Bozhok, Alla, PhD and Magazzù, Domenico, PhD and Heinzmann, Dominik, PhD and Steinseifer, Jutta, PhD and Valagussa, Pinuccia, BS and Baselga, Jose, MD
The lancet oncology, ISSN 1470-2045, 2014, Volume 15, Issue 6, pp. 640 - 647
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Antibodies, Monoclonal, Humanized - adverse effects | Follow-Up Studies | Inflammatory Breast Neoplasms - pathology | Humans | Middle Aged | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Antineoplastic Agents - administration & dosage | Breast Neoplasms - drug therapy | Disease-Free Survival | Antibodies, Monoclonal, Humanized - administration & dosage | Antineoplastic Agents - adverse effects | Breast Neoplasms - pathology | Genes, erbB-2 | Inflammatory Breast Neoplasms - drug therapy | Adult | Breast Neoplasms - mortality | Female | Neoadjuvant Therapy | Aged | Chemotherapy, Adjuvant | Trastuzumab | Inflammatory Breast Neoplasms - mortality | Antimitotic agents | Care and treatment | Breast cancer | Antineoplastic agents | Analysis | Chemotherapy | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
by Swain, Sandra M and Baselga, José and Kim, Sung-Bae and Ro, Jungsil and Semiglazov, Vladimir and Campone, Mario and Ciruelos, Eva and Ferrero, Jean-Marc and Schneeweiss, Andreas and Heeson, Sarah and Clark, Emma and Ross, Graham and Benyunes, Mark C and Cortés, Javier and CLEOPATRA Study Grp and CLEOPATRA Study Group
The New England journal of medicine, ISSN 0028-4793, 02/2015, Volume 372, Issue 8, pp. 724 - 734
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Antibodies, Monoclonal, Humanized - adverse effects | Double-Blind Method | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Breast Neoplasms - drug therapy | Taxoids - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Neoplasm Metastasis - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Survival Analysis | Adult | Breast Neoplasms - mortality | Female | Aged | Receptor, ErbB-2 | Infusions, Intravenous | Trastuzumab | Care and treatment | Pertuzumab | Docetaxel | Breast cancer | Dosage and administration | Diagnosis | Research | Chemotherapy | Epidermal growth factor | Sensitivity analysis | Survival | ErbB-2 protein | Clinical outcomes | Metastases | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
by Gianni, Luca, Dr and Eiermann, Wolfgang, MD and Semiglazov, Vladimir, MD and Manikhas, Alexey, MD and Lluch, Ana, MD and Tjulandin, Sergey, MD and Zambetti, Milvia, MD and Vazquez, Federico, MD and Byakhow, Mikhail, MD and Lichinitser, Mikhail, MD and Climent, Miguel Angel, MD and Ciruelos, Eva, MD and Ojeda, Belén, MD and Mansutti, Mauro, MD and Bozhok, Alla, MD and Baronio, Roberta, MSci and Feyereislova, Andrea, MD and Barton, Claire, MD and Valagussa, Pinuccia and Baselga, Jose, MD
The Lancet (British edition), ISSN 0140-6736, 2010, Volume 375, Issue 9712, pp. 377 - 384
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Cyclophosphamide - administration & dosage | Adenocarcinoma - pathology | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Antibodies, Monoclonal, Humanized | Fluorouracil - administration & dosage | Time Factors | Adult | Female | Neoadjuvant Therapy | Chemotherapy, Adjuvant | Paclitaxel - administration & dosage | Receptor, ErbB-2 - drug effects | Doxorubicin - administration & dosage | Proportional Hazards Models | Combined Modality Therapy | Adenocarcinoma - drug therapy | Breast Neoplasms - drug therapy | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Genes, erbB-2 - genetics | Methotrexate - administration & dosage | Infusions, Intravenous | Trastuzumab | Chemotherapy | Breast cancer | Womens health | Cancer therapies | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial
by von Minckwitz, Gunter, Prof and Puglisi, Fabio, MD and Cortes, Javier, MD and Vrdoljak, Eduard, Prof and Marschner, Norbert, MD and Zielinski, Christoph, Prof and Villanueva, Cristian, MD and Romieu, Gilles, MD and Lang, István, Prof and Ciruelos, Eva, MD and De Laurentiis, Michele, MD and Veyret, Corinne, Prof and de Ducla, Sabine, DEA and Freudensprung, Ulrich, MSc and Srock, Stefanie, MD and Gligorov, Joseph, MD
The lancet oncology, ISSN 1470-2045, 2014, Volume 15, Issue 11, pp. 1269 - 1278
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Neoplasm Recurrence, Local - drug therapy | Neoplasm Recurrence, Local - mortality | Bevacizumab | Patient Selection | Dose-Response Relationship, Drug | Neoplasm Recurrence, Local - pathology | Antibodies, Monoclonal, Humanized - administration & dosage | Time Factors | Neoplasm Invasiveness - pathology | Adult | Remission Induction - methods | Antibodies, Monoclonal, Humanized - adverse effects | Drug Administration Schedule | Treatment Outcome | Breast Neoplasms - drug therapy | Disease-Free Survival | Retreatment | Maximum Tolerated Dose | Breast Neoplasms - genetics | Breast Neoplasms - pathology | Genes, erbB-2 - genetics | Survival Analysis | Breast Neoplasms - mortality | Aged | Neoplasm Staging | Medical colleges | Care and treatment | Relapse | Chemotherapy | Breast cancer | Metastasis | Angiogenesis inhibitors | Diseases | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Adjuvant Ovarian Suppression in Premenopausal Breast Cancer
by Francis, Prudence A and Regan, Meredith M and Fleming, Gini F and Láng, István and Ciruelos, Eva and Bellet, Meritxell and Bonnefoi, Hervé R and Climent, Miguel A and Da Prada, Gian Antonio and Burstein, Harold J and Martino, Silvana and Davidson, Nancy E and Geyer, Charles E and Walley, Barbara A and Coleman, Robert and Kerbrat, Pierre and Buchholz, Stefan and Ingle, James N and Winer, Eric P and Rabaglio-Poretti, Manuela and Maibach, Rudolf and Ruepp, Barbara and Giobbie-Hurder, Anita and Price, Karen N and Colleoni, Marco and Viale, Giuseppe and Coates, Alan S and Goldhirsch, Aron and Gelber, Richard D and Int Breast Canc Study Grp and SOFT Investigators and International Breast Cancer Study Group
The New England journal of medicine, ISSN 0028-4793, 01/2015, Volume 372, Issue 5, pp. 436 - 446
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Breast Neoplasms - surgery | Premenopause | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Breast Neoplasms - drug therapy | Antineoplastic Agents, Hormonal - adverse effects | Disease-Free Survival | Aromatase Inhibitors - adverse effects | Breast Neoplasms - radiotherapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antineoplastic Agents, Hormonal - therapeutic use | Tamoxifen - therapeutic use | Mastectomy | Adult | Female | Androstadienes - therapeutic use | Chemotherapy, Adjuvant | Tamoxifen - adverse effects | Androstadienes - adverse effects | Aromatase Inhibitors - therapeutic use | Chemotherapy | Womens health | Invasiveness | Estrogens | Population studies | Breast cancer | Reproductive system | Tamoxifen | Drug therapy | Survival | Patients | Statistical analysis | Endocrine therapy | Radiation therapy | Cancer therapies | Survival analysis | Health risk assessment | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights